Clonidine Hydrochloride Extended-Release Suspension - Uses, Dosage, Precautions, Side Effects, and Pharmacological Aspects

Overview

Clonidine hydrochloride extended-release suspension is a medication used in the treatment of attention-deficit hyperactivity disorder (ADHD). It functions by altering specific neurotransmitters in the brain to improve focus, reduce impulsivity, and manage hyperactivity in children. This extended-release formulation provides steady medication levels throughout the day, enhancing its effectiveness in managing ADHD (a neurodevelopmental disorder) symptoms. On May 30, 2024, the US FDA (United States Food and Drug Administration) approved Clonidine hydrochloride extended-release suspension as a non-stimulant liquid treatment for ADHD.

Drug Group

Clonidine hydrochloride extended-release suspension belongs to the drug class known as alpha2-adrenergic agonists. These medications work by stimulating alpha2-adrenergic receptors in the brain, leading to various therapeutic effects, including the treatment of conditions like hypertension (high blood pressure) and attention deficit hyperactivity disorder.

Indications

Clonidine hydrochloride extended-release suspension is a medication that acts centrally as an alpha2-adrenergic agonist. It is used for treating ADHD either alone or in combination with central nervous system (CNS) stimulant medications in pediatric patients aged six years and older.

Dosage Forms and Available Strengths

Clonidine hydrochloride extended-release oral suspension is a light beige to tan viscous liquid containing 0.1 mg (milligrams) of Clonidine hydrochloride per mL (milliliter).

For Patients

What Is ADHD?

ADHD, or attention deficit hyperactivity disorder, is a neurodevelopmental condition marked by inattention, hyperactivity (excessive movement), and impulsivity (hasty actions). It impacts both children and adults, resulting in challenges with concentration, organizing tasks, and controlling impulses.

• Symptoms: The symptoms include trouble sustaining attention, excessive fidgeting or restlessness, and impulsively interrupting others.

• Causes: Likely a combination of genetic, environmental, and neurological factors.

• Diagnosis: Involves comprehensive evaluation by a healthcare professional to assess symptoms and rule out other conditions.

• Treatment: Often includes medication (stimulants or non-stimulants), behavioral therapy to teach coping strategies, and educational support.

• Outlook: With proper management, individuals with ADHD can lead successful lives, though ongoing support may be needed.

How Does the Clonidine Hydrochloride Extended-Release Suspension Work?

Clonidine hydrochloride extended-release suspension works by stimulating alpha2-adrenergic receptors in the brain. This action helps regulate neurotransmitter release, reducing symptoms of ADHD such as hyperactivity, impulsivity, and inattention. The extended-release formulation ensures consistent medication levels for effective symptom management with once-daily dosing.

What Are the Benefits of the Clonidine Hydrochloride Extended-Release Suspension?

• Clonidine hydrochloride extended-release suspension is an effective treatment for ADHD symptoms in pediatric patients aged six years and older.

• Once-daily dosing with extended-release formulation for continuous medication delivery.

• Allows for customizable dosage adjustments based on individual responses.

• It can be used alone or in combination with other ADHD therapies, such as CNS stimulants.

• Designed for ease of use with specialized dosing dispenser and storage instructions.

• Clinically proven safety and efficacy through rigorous testing and regulatory approval.

What Is the Dosage of the Clonidine Hydrochloride Extended-Release Suspension?

• Start with 0.1 mg of Clonidine hydrochloride orally once daily at bedtime, with or without food.

• Based on its effectiveness, increase the dose by 0.1 mg per day each week, up to a maximum of 0.4 mg once daily at bedtime.

• Doses higher than 0.4 mg once daily were not studied for ADHD and should not be used.

• If Clonidine hydrochloride is used with a CNS stimulant, adjust the stimulant dose based on the response to Clonidine hydrochloride.

How Are Clonidine Hydrochloride Extended-Release Suspension Administered?

1. Administration Instructions:

• Use the provided oral dosing dispenser and bottle adapter.

• Insert the bottle adapter securely and keep it in place during use.

• Shake Clonidine hydrochloride gently for at least 10 seconds before each use to mix it properly (avoid foaming).

• Dispose of any Clonidine hydrochloride remaining in the bottle after 60 days of opening.

2. Switching from Other Clonidine Products:

• Stop using other Clonidine products and start using Clonidine hydrochloride using the recommended titration schedule.

• Do not switch directly based on milligram amounts due to differences in how the medications work.

3. Discontinuation:

• When stopping Clonidine hydrochloride, decrease the daily dose gradually by no more than 0.1 mg every three to seven days to prevent rebound high blood pressure.

What Are the Side Effects of Clonidine Hydrochloride Extended-Release Suspension?

Common Side Effects:

• Drowsiness.

• Fatigue.

• Irritability.

• Nightmares.

• Insomnia (trouble sleeping).

• Constipation.

• Dry mouth.

• Decreased appetite.

• Dizziness.

• Headache.

• Abdominal pain.

Serious Side Effects - Seek Medical Attention Immediately:

• Sudden vision changes (loss of vision, blurred vision, tunnel vision).

• Eye pain or swelling.

• Fast, irregular, or pounding heartbeats.

• Fluttering in the chest.

• Shortness of breath.

• Sudden dizziness, lightheadedness, or fainting.

• Severe headache.

• Confusion.

• Slurred speech.

• Weakness in arms or legs.

• Trouble walking or loss of coordination.

• Stiff muscles.

• High fever.

• Profuse sweating.

• Tremors.

What Are the Things to Inform the Doctor Before Taking Clonidine Hydrochloride Extended-Release Suspension?

Before taking Clonidine hydrochloride extended-release suspension, inform the doctor about any medical conditions (especially heart, kidney, or liver disease), allergies, current medications (including supplements), pregnancy or breastfeeding status, previous experience with Clonidine, substance use history, upcoming surgeries, and any other relevant health conditions. This information helps ensure the safe and effective use of the medication.

Dietary Considerations

When taking Clonidine hydrochloride extended-release suspension, maintain a consistent diet, stay hydrated, follow medication instructions regarding food, avoid alcohol, ensure nutrient balance, and discuss any concerns with the healthcare provider.

Missed Dose

If a dose of Clonidine hydrochloride suspension is missed, skip that dose and take the next dose as scheduled. Do not exceed the prescribed total daily amount of Clonidine hydrochloride in any 24 hours.

Overdose

Hypertension may occur initially, followed by hypotension (low blood pressure), bradycardia (low heart rate), respiratory depression, hypothermia (low body temperature), drowsiness, reduced or absent reflexes, weakness, irritability, and pupil constriction. CNS depression is more common in pediatric patients than in adults. Large overdoses can cause reversible heart conduction defects or arrhythmias (abnormal heart rhythms), apnea (temporary cessation or pause in breathing), coma (a profound state of unconsciousness), and seizures (uncontrolled electrical disturbances in the brain). Overdose symptoms typically appear within 30 minutes to two hours after exposure.

Storage and Handling

• Clonidine hydrochloride extended-release oral suspension 0.1 mg/mL (milligram per milliliter) is a light beige to tan viscous liquid. It is available in 120 mL bottles with child-resistant caps and comes with two oral dosing dispensers and two bottle adapters.

• Store Clonidine hydrochloride extended-release oral suspension at a temperature range of 20°C or degrees Celsius to 25°C (68°F or degrees Fahrenheit to 77°F), with excursions allowed between 15°C and 30°C (59°F to 86°F). Protect it from light. Keep Clonidine hydrochloride extended-release oral suspension in the original bottle and use the supplied adapter and dispenser.

Disposal:

It is important to note that any unused suspension should be discarded after 60 days of opening to ensure safety and effectiveness.

For Doctors

Chemical Taxonomy

Active Ingredient: Clonidine hydrochloride, a centrally acting alpha2-adrenergic agonist.

Chemical Information:

• Clonidine hydrochloride is an imidazoline derivative.

• Chemical Name: 2-[(2,6-dichlorophenyl)imino]imidazolidine hydrochloride.

• Molecular Formula: C9H9Cl2N3•HCl.

• Molecular Weight: 266.5 daltons.

• pKa: 8.05.

• Appearance: Odorless, bitter, white to almost white crystalline powder, soluble in water and alcohol.

• pH of a five percent water solution: 3.5 to 5.5.

Formulation:

• Clonidine hydrochloride is an extended-release suspension for oral use.

• Each mL contains 0.09 mg clonidine, equivalent to 0.1 mg Clonidine hydrochloride.

• pH of Clonidine hydrochloride is 2.8 to 4.

Inactive Ingredients:

• Anhydrous citric acid.

• Edetate disodium.

• Glycerin.

• Modified starch.

• Methylparaben.

• Orange flavor.

• Polyvinyl acetate dispersion is 30 percent.

• Povidone.

• Polysorbate 80.

• Propylparaben.

• Purified water.

• Sucrose.

• Sodium polystyrene sulfonate.

• Triacetin.

• Xanthan gum.

Warnings and Precautions

1. Hypotension and Bradycardia:

• Clonidine hydrochloride suspension may lower blood pressure and heart rate.

Monitoring heart rate and blood pressure before starting treatment, after the dose increases, and periodically during therapy is crucial. This responsibility ensures the safety and well-being of the patient. Adjust Clonidine hydrochloride cautiously in patients with a low blood pressure history or conditions that may worsen with low blood pressure.

2. Sedation and Somnolence:

• Somnolence and sedation are common side effects.

• Patients should refrain from driving or operating heavy machinery until they know how Clonidine hydrochloride affects them.

• Caution is advised against combining Clonidine hydrochloride with alcohol or other sedatives due to potential additive effects.

3. Rebound Hypertension:

• Abruptly stopping Clonidine hydrochloride can lead to rebound hypertension.

• To minimize this risk, gradually decrease the dose under medical supervision.

4. Allergic Reactions:

• Certain individuals might experience allergic responses, such as skin rashes or swelling.

• Monitor for allergic symptoms and discontinue Clonidine hydrochloride if an allergic reaction occurs.

5. Cardiac Conduction Abnormalities:

• Clonidine hydrochloride may worsen heart rhythm problems, especially in patients using other drugs affecting heart function.

• Monitor patients with existing heart conditions closely during the treatment.

What Are the Pharmacological Actions of Clonidine Hydrochloride Extended-Release Suspension?

Mechanism of Action: Clonidine stimulates alpha2-adrenergic receptors in the brain, but it is not a central nervous system stimulant. The exact mechanism by which clonidine works in treating ADHD is unknown.

Pharmacodynamics: Clonidine is an antihypertensive agent. It stimulates alpha2-adrenergic receptors in the brain stem, which reduces sympathetic outflow from the central nervous system. This results in decreased peripheral resistance, renal vascular resistance, heart rate, and blood pressure.

Pharmacokinetics

Absorption:

• Single 0.2 mg dose of Clonidine hydrochloride peaks (Tmax) at 7.5 hours.

• Peak concentration (Cmax) is 95.6 percent of Clonidine extended-release tablets.

• Relative bioavailability is 96.1 percent compared to extended-release tablets.

• After five days of 0.2 mg Clonidine hydrochloride daily, peak plasma concentration is 107.9 percent, and bioavailability is 97.7 percent of clonidine extended-release tablets.

• The minimum steady-state concentration is 26 percent lower for Clonidine hydrochloride.

Comparison:

Immediate-release clonidine peaks in three to five hours.

Peak concentration is 50 percent lower for extended-release tablets.

Effect of Food: Food does not affect plasma levels of Clonidine hydrochloride

Elimination: Half-life is 12 to 16 hours (up to 41 hours in severe renal impairment).

Metabolism: 50 percent of Clonidine is metabolized in the liver.

Excretion:

• 40 to 60 percent of the dose is excreted unchanged in urine within 24 hours.

• The Clonidine hydrochloride excretion profile is similar to immediate-release Clonidine.

Specific Populations:

Pediatric Patients:

• Higher plasma concentrations in children (six to 17 years) with ADHD compared to adults.

• Higher clearance (CL/F) in children.

• Clonidine concentrations increase with dose.

• Females have 23 percent lower clearance than males.

• Sedation-related events are dose-independent.

Drug Interaction Studies:

Alcohol:

• Twenty percent alcohol significantly increases and varies Clonidine hydrochloride drug release.

• Five to ten percent alcohol does not affect drug release.

Non-Clinical Toxicity

• Carcinogenicity: Clonidine hydrochloride did not cause cancer in rats or mice. Tested doses up to 25 times higher than the recommended human dose showed no cancerous effects.

• Mutagenicity: Clonidine hydrochloride did not cause genetic mutations. Tests for mutagenicity and chromosomal damage were negative.

• Effects on Fertility: High doses of Clonidine hydrochloride affected fertility in female rats. Lower doses were not thoroughly studied, so a safe level without fertility effects is unknown.

What Are the Contraindications of Clonidine Hydrochloride Extended-Release Suspension?

Clonidine hydrochloride is contraindicated in patients with a history of hypersensitivity to Clonidine. Reactions have included generalized rash, urticaria (hives), and angioedema (deep skin swelling).

What Are the Drug Interactions of Clonidine Hydrochloride Extended-Release Suspension?

Clonidine hydrochloride extended-release suspension has significant drug interactions:

• Antihypertensive Drugs: Enhances blood pressure-lowering effects.

• CNS Depressants: Increases sedative effects. Avoid concurrent use.

• Drugs Affecting Sinus Node Function or AV Node Conduction (for example, Digitalis, Calcium Channel Blockers, Beta-blockers): Increases risk of bradycardia and AV block. Avoid concurrent use.

• Tricyclic Antidepressants: May elevate blood pressure and counteract Clonidine's effects.

• MAO Inhibitors: Theymay affect efficacy and safety, so use caution and monitor them.

• Alcohol: Enhances CNS depressant effect. Avoid alcohol.

• Beta-Blockers: Risk of severe bradycardia or rebound hypertension if Clonidine is abruptly discontinued. Gradually discontinue and monitor.

Clinical Studies

Clonidine hydrochloride's effectiveness in treating ADHD in children aged six years and older is supported by rigorous studies of Clonidine hydrochloride extended-release tablets.

1. Study Overview:

The efficacy was established in:

• One short-term placebo-controlled monotherapy trial (study 1).

• One short-term adjunctive therapy to psychostimulants trial (study 2).

• One randomized withdrawal trial as monotherapy (study 3).

2. Clinical Trials: These trials involved pediatric patients meeting DSM-IV criteria for ADHD hyperactive, combined hyperactive, or inattentive subtypes. They used standardized ADHD assessment scales to measure symptom improvements.

3. Results: Significant improvements in ADHD symptoms were observed with Clonidine hydrochloride compared to placebo and psychostimulant alone.

4. Long-Term Efficacy: Study 3 demonstrated sustained efficacy over a 26-week double-masked phase, with fewer patients experiencing treatment failure than placebo.

5. Conclusion: The studies provide robust evidence supporting the efficacy of Clonidine hydrochloride in managing ADHD symptoms in pediatric patients.

Use in Specific Populations

• Pregnancy: Studies show no major risk of birth defects or miscarriage. Animal studies indicate some risks at high doses.

• Lactation: Clonidine is found in breast milk. Most infants have no issues, but watch for sedation and low blood pressure. Monitor infants for drowsiness, slow feeding, or breathing issues.

• Reproductive Potential: According to animal studies, Clonidine hydrochloride may reduce fertility in both males and females.

• Pediatric Use: Safe for ADHD treatment in children six to 17 years old. Not established for children under six.

• Renal Impairment: Adjust the dose for patients with kidney issues. No extra dose is needed after dialysis. Monitor for low blood pressure and slow heart rate.